- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT01481454
Study of a Quadrivalent Influenza Vaccine Administered Intramuscularly in Children/Adolescents and Adults
Safety and Immunogenicity of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Child/Adolescent and Adult Subjects
The aim of the study is to assess the safety profile of a quadrivalent influenza vaccine (QIV) and to demonstrate that 3 different industrial lots of QIV induce an equivalent immune response in children/adolescents (9 to 17 years of age) and adults (18 to 60 years of age).
Primary Objective:
- To describe the safety profile (injection site reactions and systemic events) of each vaccine during the 21 days following vaccination, and serious adverse events (including adverse events of special interest) throughout the study in all adult and child/adolescent participants.
Secondary Objectives:
- To demonstrate that the 3 different industrial lots of quadrivalent influenza vaccine (QIV) induce an equivalent immune response at 21 days post-vaccination in both age groups (lot consistency)
- To describe the compliance of the immunogenicity of QIV to the European Medicines Agency Note for Guidance (NfG) (CPMP/BWP/214/96) in each age group.
Przegląd badań
Status
Warunki
Szczegółowy opis
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 3
Kontakty i lokalizacje
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Aged 9 to 11 years (children), 12 to 17 years (adolescents), or 18 to 60 years (adults) on the day of inclusion
- For child/adolescent subjects, informed consent form has been signed and dated by the parent(s) (and subject, if applicable by local regulations), or another legally acceptable representative (and independent witness, if required by local regulations), and the assent form has been signed and dated by the subject (if applicable by the local Ethics Committee or country regulations). For adult subjects, informed consent form has been signed and dated by the subject (and an independent witness, if required by local regulations).
- Subject/subject and parent/legally acceptable representative is/are able to attend all scheduled visits and to comply with all trial procedures
- Covered by health insurance, if required by local regulation.
Exclusion Criteria:
- Subject is pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be pre-menarche or post-menopausal for at least 1 year, surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to vaccination and until at least 4 weeks after vaccination)
- Participation at the time of study enrollment or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure
- Receipt of any vaccine in the 4 weeks preceding trial vaccination or planned receipt of any vaccine in the 3 weeks following trial vaccination
- Previous vaccination against influenza with the 2012 Southern Hemisphere formulation or the 2011-2012 Northern Hemisphere formulation in the previous 6 months with either the trial vaccine or another vaccine
- Receipt of immune globulins, blood or blood-derived products in the past 3 months
- Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
- Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances
- Self-reported thrombocytopenia, contraindicating intramuscular vaccination based on investigator's judgment
- Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination based on investigator's judgment
- Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
- Current alcohol abuse or drug addiction (for adolescent and adult subjects)
- Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion
- Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 38.0°C). A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided
- Identified as an investigator or employee of the investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural, or adopted child) of the investigator or employee with direct involvement in the proposed study.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Zapobieganie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Poczwórny
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Group 1: QIV Lot 1
Participants will receive the Quadrivalent Influenza Vaccine (QIV) from Lot 1.
|
0,5 ml, domięśniowo
|
Eksperymentalny: Group 2: QIV Lot 2
Participants will receive the Quadrivalent Influenza Vaccine (QIV) from Lot 2.
|
0,5 ml, domięśniowo
|
Eksperymentalny: Group 3: QIV Lot 3
Participants will receive the Quadrivalent Influenza Vaccine (QIV) from Lot 3.
|
0,5 ml, domięśniowo
|
Aktywny komparator: Group 4: TIV
Participants will receive the Trivalent Influenza Vaccine (TIV).
|
0.5 mL, Intramuscular
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Percentage of participants reporting solicited injection site reactions and solicited systemic reactions during the trial
Ramy czasowe: Day 0 to 7 post-vaccination
|
Solicited Injection Site Reactions: Pain, Erythema, Swelling, Induration, and Ecchymosis.
Solicited Systemic Reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Shivering
|
Day 0 to 7 post-vaccination
|
Percentage of participants reporting unsolicited systemic reactions including serious adverse events (SAE) throughout the trial.
Ramy czasowe: Day 0 up to six months post-vaccination
|
An SAE is defined as any untoward medical occurrence that at any dose (including overdose): Results in death; Is life-threatening; Requires inpatient hospitalization or prolongation of existing hospitalization; Results in persistent or significant disability / incapacity; Is a congenital anomaly / birth defect; Is an important medical event.
|
Day 0 up to six months post-vaccination
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Percentage of participants with seroprotection and seroconversion post vaccination with either the investigational QIV, or TIV or the licensed 2011-2012 TIV
Ramy czasowe: Day 21 post-vaccination
|
Immunogenicity assessed by hemagglutination inhibition (HAI) assay for each vaccine strain. Seroprotection defined as a post-vaccination titer of ≥ 40 (1/dil); Seroconversion defined for participants with a pre-vaccination titer < 10 (1/dil) and a post-vaccination titer of ≥ 40 (1/dil). |
Day 21 post-vaccination
|
Level of anti-hemagglutinin antibody titers for each of the 4 strains for each lot of the investigational QIV vaccine.
Ramy czasowe: 21 Days post-vaccination
|
21 Days post-vaccination
|
Współpracownicy i badacze
Sponsor
Publikacje i pomocne linki
Przydatne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- GQM04
- U1111-1122-2719 (Inny identyfikator: WHO)
- 2011-005101-79 (Numer EudraCT)
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Grypa
-
Mitsubishi Tanabe Pharma CorporationZakończony
-
Mexican Emerging Infectious Diseases Clinical Research...National Institute of Allergy and Infectious Diseases (NIAID); Coordinación...ZakończonyOstre infekcje dróg oddechowych | Influenza Nos lub choroba grypopodobnaMeksyk
-
Jiangsu Province Centers for Disease Control and...Chengdu Olymvax Biopharmaceuticals Inc.Zakończony
-
Jiangsu Province Centers for Disease Control and...Royal (Wuxi) Biological Co., LTDZakończonyGrupa A, C Polisacharydowe zapalenie opon mózgowych | Haemophilus influenza typu bChiny
-
University Hospital, LilleCSL Behring; Laboratoire français de Fractionnement et de Biotechnologies; Oct... i inni współpracownicyZakończonyInfekcje pneumokokowe | Zapalenie płuc, bakteryjne | Zapalenie opon mózgowych, bakteryjne | Zapalenie ucha środkowego | Przewlekła infekcja zatok | Infekcja paciorkowcowa | Niedobór przeciwciał | Niedobór dopełniacza | Zakażenia Neisseria | Haemophilus InfluenzaFrancja
-
QIAGEN Gaithersburg, IncZakończonyZakażenia syncytialnym wirusem oddechowym | Grypa A | Rinowirus | Grypa B | Panel zaawansowany QIAGEN ResPlex II | Zakażenie wywołane ludzkim wirusem paragrypy 1 | Paragrypa typu 2 | Paragrypa typu 3 | Paragrypa typu 4 | Ludzki metapneumowirus A/B | Wirus Coxsackie/echowirus | Adenowirusy typu B/C/E | Podtypy koronawirusa... i inne warunkiStany Zjednoczone